Skip to main content
Fig. 6 | Journal of Translational Medicine

Fig. 6

From: A novel patient-derived organoids-based xenografts model for preclinical drug response testing in patients with colorectal liver metastases

Fig. 6

PDOX-LM model mimic patient’s response to chemotherapy. a Summary of clinical history of donor patient with initially unresectable liver or lung metastases. The clinical course of the patients with unresectable metastases accepting conversion therapy is summarized. Red-lined boxes indicate periods of administration of the indicated therapeutic regiments. Blue vertical lines indicate timing of tumor specimen acquisition from surgical procedures, PDOs model or PDOX-LM model establishment as well as dates of drug test starting and drug-response assessed by overall survival of murine model. PR, partial response, PD, progressive disease; according to RECIST (Response Evaluation Criteria in Solid Tumors) 1.1. b PDOX-LM models were generated from primary tumor biopsies of patients with unresectable liver metastases (patient #3 and #5, red circles in the bottom panel) that showed initial response to mFOLFOX6 regiments. Violet bars indicate overall tumor volume [according to RECIST 1.1], and red bars indicate volume of the target metastasis. c Kaplan–Meier survival curve showing a significant increase in the survival of PR group compared to both PD group and control group. NOTE: PR group: PDOX-LM models derived from the donor patients with a clinical drug response of PR (RECIST 1.1) were tested for oxaliplatin and 5-Fu. PD group: PDOX-LM models derived from the donor patients with a clinical drug response of PD (RECIST 1.1) were tested for the combination of oxaliplatin and 5-Fu. NS: Not significant, p-value ≥ 0.05, ***p-value ≤ 0.001

Back to article page